Literature DB >> 9744700

Octreotide in the treatment of intestinal lymphangiectasia.

A B Ballinger1, M J Farthing.   

Abstract

Primary intestinal lymphangiectasia is characterized by dilated small bowel lymphatics and loss of lymph into the bowel lumen resulting in hypoproteinaemia and oedema. Some patients have a more generalized lymphatic abnormality associated with lymphoedema of the limbs and chylous pleural effusions. There is no specific treatment although enteric protein loss may decrease with a low-fat diet. This report describes a patient with severe primary intestinal lymphangiectasia, associated with limb oedema and recurrent pleural effusions, who responded to treatment with octreotide. Before starting octreotide she required weekly intravenous albumin infusions to maintain the serum albumin above 20 g/l. Bilateral pleural effusions repeatedly reaccumulated despite pleurectomy and subsequently tetracycline pleurodesis. Treatment with octreotide, 200 microg twice daily, resulted in a reduction in enteric protein loss from 16 to 4.1% in 5 days (normal less than 1%) and the serum albumin was maintained between 22 and 26 g/l without the need for albumin infusion. Oedema in the arms resolved completely and the pleural effusions did not reaccumulate. The mechanism of action of octreotide in this condition appears to be due to a reduction in gut protein loss and another, as yet unidentified, action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744700

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  20 in total

1.  Type I intestinal lymphangiectasia treated successfully with slow-release octreotide.

Authors:  R D Klingenberg; N Homann; D Ludwig
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  Enteral nutrition as a primary therapy for intestinal lymphangiectasia: value of elemental diet and polymeric diet compared with total parenteral nutrition.

Authors:  Kunihiko Aoyagi; Mitsuo Iida; Takayuki Matsumoto; Shotaro Sakisaka
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

3.  Anaemia in Waldmann's disease: A rare presentation of a rare disease.

Authors:  Shahira A El-Etreby; Ahmed Y Altonbary; Mohamed El Sorogy; Wagdi Elkashef; Jehan A Mazroa; Monir H Bahgat
Journal:  World J Gastrointest Endosc       Date:  2015-05-16

4.  How to treat an extensive form of primary intestinal lymphangiectasia?

Authors:  Rosana Troskot; Dragan Jurčić; Ante Bilić; Marija Gomerčić Palčić; Stanko Težak; Ivana Brajković
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 5.  Primary intestinal lymphangiectasia: four case reports and a review of the literature.

Authors:  Jie Wen; Qingya Tang; Jiang Wu; Ying Wang; Wei Cai
Journal:  Dig Dis Sci       Date:  2010-03-03       Impact factor: 3.199

6.  Protein-Losing Enteropathy and Gastropathy.

Authors:  Brian R. Landzberg; Mark B. Pochapin
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

7.  [Chronic diarrhea in a 43-year-old patient].

Authors:  J Strehl; M Schepke; E Wardelmann; W H Caselmann; T Sauerbruch
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

8.  Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia.

Authors:  Siham Al Sinani; Yusria Al Rawahi; Hamed Abdoon
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

9.  Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report.

Authors:  Hang Lak Lee; Dong Soo Han; Jin Bae Kim; Yong Chul Jeon; Joo Hyun Sohn; Joon Soo Hahm
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

10.  Primary intestinal lymphangiectasia diagnosed by double-balloon enteroscopy and treated by medium-chain triglycerides: a case report.

Authors:  Yu Lai; Tao Yu; Xiao-Yu Qiao; Li-Na Zhao; Qi-Kui Chen
Journal:  J Med Case Rep       Date:  2013-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.